• Je něco špatně v tomto záznamu ?

Accelerated re-epithelialization of partial-thickness skin wounds by a topical betulin gel: Results of a randomized phase III clinical trials program

JP. Barret, F. Podmelle, B. Lipový, HO. Rennekampff, H. Schumann, A. Schwieger-Briel, TR. Zahn, HR. Metelmann, . ,

. 2017 ; 43 (6) : 1284-1294. [pub] 20170408

Jazyk angličtina Země Nizozemsko

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18025089

The clinical significance of timely re-epithelialization is obvious in burn care, since delayed wound closure is enhancing the risk of wound site infection and extensive scarring. Topical treatments that accelerate wound healing are urgently needed to reduce these sequelae. Evidence from preliminary studies suggests that betulin can accelerate the healing of different types of wounds, including second degree burns and split-thickness skin graft wounds. The goal of this combined study program consisting of two randomized phase III clinical trials in parallel is to evaluate whether a topical betulin gel (TBG) is accelerating re-epithelialization of split-thickness skin graft (STSG) donor site wounds compared to standard of care. Two parallel blindly evaluated, randomised, controlled, multicentre phase III clinical trials were performed in adults undergoing STSG surgery (EudraCT nos. 2012-003390-26 and 2012-000777-23). Donor site wounds were split into two equal halves and randomized 1:1 to standard of care (a non-adhesive moist wound dressing) or standard of care plus TBG consisting of 10% birch bark extract and 90% sunflower oil (Episalvan, Birken AG, Niefern-Oeschelbronn, Germany). The primary efficacy assessment was the intra-individual difference in time to wound closure assessed from digital photographs by three blinded experts. A total of 219 patients were included and treated in the two trials. Wounds closed faster with TBG than without it (15.3 vs. 16.5 days; mean intra-individual difference=-1.1 days [95% CI, -1.5 to -0.7]; p<0.0001). This agreed with unblinded direct clinical assessment (difference=-2.1 days [95% CI, -2.7 to -1.5]; p<0.0001). Adverse events possibly related to treatment were mild or moderate and mostly at the application site. TBG accelerates re-epithelialization of partial thickness wounds compared to the current standard of care, providing a well-tolerated contribution to burn care in practice.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18025089
003      
CZ-PrNML
005      
20230329093437.0
007      
ta
008      
180709s2017 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.burns.2017.03.005 $2 doi
035    __
$a (PubMed)28400148
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Barret-Nerín, Juan Pedro, $u Department of Plastic Surgery and Burns, University Hospital Vall d'Hebron, Passeig de la Vall d'Hebron 119-129, 08035 Barcelona, Spain. Electronic address: jpbarret@vhebron.net. $d 1967- $7 xx0284254
245    10
$a Accelerated re-epithelialization of partial-thickness skin wounds by a topical betulin gel: Results of a randomized phase III clinical trials program / $c JP. Barret, F. Podmelle, B. Lipový, HO. Rennekampff, H. Schumann, A. Schwieger-Briel, TR. Zahn, HR. Metelmann, . ,
520    9_
$a The clinical significance of timely re-epithelialization is obvious in burn care, since delayed wound closure is enhancing the risk of wound site infection and extensive scarring. Topical treatments that accelerate wound healing are urgently needed to reduce these sequelae. Evidence from preliminary studies suggests that betulin can accelerate the healing of different types of wounds, including second degree burns and split-thickness skin graft wounds. The goal of this combined study program consisting of two randomized phase III clinical trials in parallel is to evaluate whether a topical betulin gel (TBG) is accelerating re-epithelialization of split-thickness skin graft (STSG) donor site wounds compared to standard of care. Two parallel blindly evaluated, randomised, controlled, multicentre phase III clinical trials were performed in adults undergoing STSG surgery (EudraCT nos. 2012-003390-26 and 2012-000777-23). Donor site wounds were split into two equal halves and randomized 1:1 to standard of care (a non-adhesive moist wound dressing) or standard of care plus TBG consisting of 10% birch bark extract and 90% sunflower oil (Episalvan, Birken AG, Niefern-Oeschelbronn, Germany). The primary efficacy assessment was the intra-individual difference in time to wound closure assessed from digital photographs by three blinded experts. A total of 219 patients were included and treated in the two trials. Wounds closed faster with TBG than without it (15.3 vs. 16.5 days; mean intra-individual difference=-1.1 days [95% CI, -1.5 to -0.7]; p<0.0001). This agreed with unblinded direct clinical assessment (difference=-2.1 days [95% CI, -2.7 to -1.5]; p<0.0001). Adverse events possibly related to treatment were mild or moderate and mostly at the application site. TBG accelerates re-epithelialization of partial thickness wounds compared to the current standard of care, providing a well-tolerated contribution to burn care in practice.
650    _2
$a aplikace kožní $7 D000279
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a popálení $x terapie $7 D002056
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gely $x terapeutické užití $7 D005782
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a reepitalizace $7 D062326
650    12
$a transplantace kůže $7 D016038
650    _2
$a chirurgická rána $x farmakoterapie $7 D000072836
650    _2
$a výsledek terapie $7 D016896
650    _2
$a triterpeny $x terapeutické užití $7 D014315
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Podmelle, Fred $u Department of Oral and Maxillofacial Surgery/Plastic Surgery, University Medicine Greifswald, Ferdinand-Sauerbruch-Str. DZ7, 17475 Greifswald, Germany. Electronic address: podmelle@uni-greifswald.de.
700    1_
$a Lipový, Břetislav $u Department for Burns and Reconstructive Surgery, University Hospital Brno, Jihlavská 20, Brno, Czech Republic.
700    1_
$a Rennekampff, Hans-Oliver $u Division of Plastic and Aesthetic Surgery, Burn Surgery, Klinikum Leverkusen, Am Gesundheitspark 11, 51375 Leverkusen, Germany.
700    1_
$a Schumann, Hauke $u Catholic University of Applied Sciences, Karlstrasse 36, 79104 Freiburg, Germany; Department of Dermatology, University Medical Center Freiburg, Hauptstrasse 7, 79104 Freiburg, Germany.
700    1_
$a Schwieger-Briel, Agnes $u Department of Pediatric Dermatology, University Children's Hospital Zurich, Steinwiesstrasse 75, 8032 Zurich, Switzerland.
700    1_
$a Zahn, Tobias R $u Birken AG (An Amryt Pharma Company), Streiflingsweg 11, 75223 Niefern-Öschelbronn, Germany.
700    1_
$a Metelmann, Hans-Robert $u Department of Oral and Maxillofacial Surgery/Plastic Surgery, University Medicine Greifswald, Ferdinand-Sauerbruch-Str. DZ7, 17475 Greifswald, Germany.
700    1_
$a ,
773    0_
$w MED00000977 $t Burns $x 1879-1409 $g Roč. 43, č. 6 (2017), s. 1284-1294
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28400148 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20230329093435 $b ABA008
999    __
$a ok $b bmc $g 1317220 $s 1022010
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 43 $c 6 $d 1284-1294 $e 20170408 $i 1879-1409 $m Burns $n Burns $x MED00000977
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...